Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 5;172(9):583-590.
doi: 10.7326/M19-3478. Epub 2020 Mar 10.

Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis

Rochelle P Walensky  1 , Tim Horn  2 , Nicole C McCann  3 , Kenneth A Freedberg  4 , A David Paltiel  5
Affiliations

Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis

Rochelle P Walensky et al. Ann Intern Med. .

Abstract

Background: Tenofovir alafenamide-emtricitabine (F/TAF) was recently approved as a noninferior and potentially safer option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) in the United States.

Objective: To estimate the greatest possible clinical benefits and economic savings attributable to the improved safety profile of F/TAF and the maximum price payers should be willing to pay for F/TAF over generic F/TDF.

Design: Cost-effectiveness analysis.

Data sources: Published literature on F/TDF safety (in persons with and those without HIV) and the cost and quality-of-life effects of fractures and end-stage renal disease (ESRD).

Target population: Age-stratified U.S. men who have sex with men (MSM) using PrEP.

Time horizon: Five years.

Perspective: Health care sector.

Intervention: Preexposure prophylaxis with F/TAF versus F/TDF.

Outcome measures: Fractures averted, cases of ESRD averted, quality-adjusted life-years (QALYs) saved, costs, incremental cost-effectiveness ratios (ICERs), and maximum justifiable price for F/TAF compared with generic F/TDF.

Results of base-case analysis: Over a 5-year horizon, compared with F/TDF, F/TAF averted 2101 fractures and 25 cases of ESRD for the 123 610 MSM receiving PrEP, with an ICER of more than $7 million per QALY. At a 50% discount for generic F/TDF ($8300 per year) and a societal willingness to pay up to $100 000 per QALY, the maximum fair price for F/TAF was $8670 per year.

Results of sensitivity analysis: Among persons older than 55 years, the ICER for F/TAF remained more than $3 million per QALY and the maximum permissible fair price for F/TAF was $8970 per year. Results were robust to alternative time horizons and PrEP-using population sizes.

Limitation: Intermittent use and on-demand PrEP were not considered.

Conclusion: In the presence of a generic F/TDF alternative, the improved safety of F/TAF is worth no more than an additional $370 per person per year.

Primary funding source: National Institute of Allergy and Infectious Diseases, National Institute on Drug Abuse, National Institute of Mental Health, and Massachusetts General Hospital Executive Committee on Research.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. What is ‘Ending the HIV epidemic: A plan for America’? [Internet]. HIV.gov. 2019. [cited 2019 Nov 1]. Available from: https://www.hiv.gov/ending-hiv-epidemic
    1. Food and Drug Administration. FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic [Internet]. 2019. [cited 2019 Oct 28]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-second-...
    1. Food and Drug Administration. FDA Briefing Document: Meeting of the Antimicrobial Drugs Advisory Committee [Internet]. 2019. [cited 2019 Jan 6]. Available from: https://www.fda.gov/media/129607/download
    1. Hare CB, Coll J, Ruane P, Molina J-M, Mayer KH, Jessen H, et al. The Phase 3 Discover Study: daily F/TAF or F/TDF for HIV pre-exposure prophylaxis. In: Conference on Retroviruses and Opportunistic Infections 2019.
    1. Gilead. Press Releases: U.S Food and Drug Administration Approves Descovy for HIV Pre-Exposure Prophylaxis (PrEP) [Internet]. 2019. [cited 2019 Nov 3]. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2019/10/...

Publication types

MeSH terms